How much funding has ORIC Pharmaceuticals raised?

ORIC Pharmaceuticals has raised $158.0M in total funding, most recently a Bridge round.

Who are ORIC Pharmaceuticals's investors?

ORIC Pharmaceuticals's investors include The Column Group, ArrowMark Partners, EcoR1 Capital, Viking Global, Fidelity Management, Topspin Partners.

When was ORIC Pharmaceuticals founded?

ORIC Pharmaceuticals was founded in 2014.

Where is ORIC Pharmaceuticals headquartered?

ORIC Pharmaceuticals is headquartered in South San Francisco, California, United States.

What industry is ORIC Pharmaceuticals in?

ORIC Pharmaceuticals operates in Healthcare.

How many employees does ORIC Pharmaceuticals have?

ORIC Pharmaceuticals has 51-200 employees.

ORIC Pharmaceuticals

IPO

Overcoming Resistance In Cancer

Public · South San Francisco, United States · Founded 2014 · $158.0M raised

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2014
Business Model: B2B

Total Funding: $158.0M
Last Round: $55.0M BridgeJan 2019
Rounds: 3
Type: Public

About

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer (ORIC). Founded in 2014 and headquartered in South San Francisco, California, ORIC develops innovative oncology therapies targeting innate, acquired, and bypass resistance mechanisms that limit the efficacy of cancer treatments. The company's lead clinical programs include rinzimetostat (ORIC-944) and enozertinib (ORIC-114). ORIC went public in April 2020 and has raised over $900 million in private and public financing.

Summary

ORIC Pharmaceuticals is a Healthcare company based in South San Francisco, United States, founded in 2014. It has raised $158.0M in total across 3 rounds, most recently a $55.0M Bridge round in Jan 2019. Investors include The Column Group, ArrowMark Partners and EcoR1 Capital.